|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scagliotti G, Hanna N, Fossella F,
Sugarman K, Blatter J, Peterson P, Simms L and Shepherd FA: The
differential efficacy of pemetrexed according to NSCLC histology: A
review of two phase III studies. Oncologist. 14:253–263. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Santabarbara G, Maione P, Rossi A,
Palazzolo G and Gridelli C: Novel immunotherapy in the treatment of
advanced non-small cell lung cancer. Expert Rev Clin Pharmacol.
9:1571–1581. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Daud AI, Wolchok JD, Robert C, Hwu WJ,
Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al:
Programmed death-ligand 1 expression and response to the
anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin
Oncol. 34:4102–4109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bremnes RM, Busund LT, Kilvær TL, Andersen
S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA,
Kao SC and Dønnem T: The role of tumor-infiltrating lymphocytes in
development, progression, and prognosis of non-small cell lung
cancer. J Thorac Oncol. 11:789–800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teng F, Meng X, Wang X, Yuan J, Liu S, Mu
D, Zhu H, Kong L and Yu J: Expressions of CD8+TILs, PD-L1 and
Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy
decisions. Oncotarget. 7:64318–64329. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McLemore LE, Janakiram M, Albanese J,
Shapiro N, Lo Y, Zang X and Fineberg S: An immunoscore using PD-L1,
CD68, and Tumor-infiltrating Lymphocytes (TILs) to predict response
to neoadjuvant chemotherapy in invasive breast cancer. Appl
Immunohistochem Mol Morphol. 26:611–619. 2018.PubMed/NCBI
|
|
9
|
Zhang P, Ma Y, Lv C, Huang M, Li M, Dong
B, Liu X, An G, Zhang W, Zhang J, et al: Up-regulation of
programmed cell death ligand 1 promotes resistance response in
non-small cell lung cancer patients with neo-adjuvant chemotherapy.
Cancer Sci. 107:1563–1571. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mesnage SJL, Auguste A, Genestie C, Dunant
A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, et
al: Neoadjuvant chemotherapy (NACT) increases immune infiltration
and programmed death-ligand 1 (PD-L1) expression in epithelial
ovarian cancer (EOC). Ann Oncol. 28:651–657. 2017.PubMed/NCBI
|
|
11
|
Vacchelli E, Aranda F, Eggermont A, Galon
J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G and Galluzzi
L: Trial watch: Chemotherapy with immunogenic cell death inducers.
Oncoimmunology. 3:e278782014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leung EY, Scott HR and McMillan DC:
Clinical utility of the pretreatment glasgow prognostic score in
patients with advanced inoperable non-small cell lung cancer. J
Thorac Oncol. 7:655–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A glasgow inflammation outcome study.
Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kalra J and Baker J: Multiplex
immunohistochemistry for mapping the tumor microenvironment.
Methods Mol Biol. 1554:237–251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bindea G, Mlecnik B, Tosolini M,
Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T,
Lafontaine L, Berger A, et al: Spatiotemporal dynamics of
intratumoral immune cells reveal the immune landscape in human
cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lippitz BE: Cytokine patterns in patients
with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lippitz BE and Harris RA: Cytokine
patterns in cancer patients: A review of the correlation between
interleukin 6 and prognosis. Oncoimmunology. 5:e10937222016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu H, Liu F, Sansas B, Kang B, Preville X,
Wu X, Chang J, Micol R, Wang J and Meng X: Typing of killer-cell
immunoglobulin-like receptors and their cognate human leukocyte
antigen class I ligands predicts survival of Chinese Han patients
with metastatic non-small-cell lung cancer. Mol Clin Oncol.
6:279–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Quoix E, Ramlau R, Westeel V, Papai Z,
Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun
D, et al: Therapeutic vaccination with TG4010 and first-line
chemotherapy in advanced non-small-cell lung cancer: A controlled
phase 2B trial. Lancet Oncol. 12:1125–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fluss R, Faraggi D and Reiser B:
Estimation of the Youden Index and its associated cutoff point.
Biom J. 47:458–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naugler WE and Karin M: The wolf in
sheep's clothing: The role of interleukin-6 in immunity,
inflammation and cancer. Trends Mol Med. 14:109–119. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang YS, Miao LY, Liu L, Cai HR, Ding JJ,
Ren SX, Zhou CC and Schmid-Bindert G: Serum cytokine levels in
patients with advanced non-small cell lung cancer: Correlation with
clinical outcome of erlotinib treatment. Chin Med J (Engl).
126:3931–3935. 2013.PubMed/NCBI
|
|
24
|
Wang Z, Wu P, Wu D, Zhang Z, Hu G, ZhaoS,
Lai Y and Huang J: Prognostic and clinicopathological significance
of serum interleukin-6 expression in colorectal cancer: A
systematic review and meta-analysis. Onco Targets Ther.
8:3793–3801. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lewis AM, Varghese S, Xu H and Alexander
HR: Interleukin-1 and cancer progression: The emerging role of
interleukin-1 receptor antagonist as a novel therapeutic agent in
cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
